MEDI4736 combined with tremelimumab results in acceptable toxicity in NSCLC patients

Advanced non-small cell lung cancer patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.